Ancilia Biosciences

Ancilia Biosciences is an early-stage biotech developing a novel approach to protect therapeutic bacteria from viral attack. The company's core innovation involves using CRISPR-Cas systems, which naturally function as a bacterial immune system, to 'vaccinate' beneficial bacteria against predatory phages. This technology is enabled by two synergistic platforms: CoVE™ for computational virome analysis and EPIC™ for engineering phage immunity. By solving a critical stability and efficacy challenge for live biotherapeutic products, Ancilia aims to enable robust microbiome-based therapies across a range of diseases.

CoVE™ (Computational Virome Engine) for virome identification and characterization, and EPIC™ (Enhancing Phage Immunity with CRISPR) for engineering phage resistance into beneficial bacteria.

The field of microbiome therapeutics is crowded, but few companies focus specifically on engineering viral resistance. Competition includes academic labs researching phage-bacteria interactions and industrial biotech firms using traditional methods to control phage contamination. Ancilia's unique integration of computational virome analysis and CRISPR-based engineering is a differentiating approach.